This study investigates advanced pancreatic cancer. The purpose of this study is to evaluate the safety and tolerability of a personalized tumor vaccine used alone or with an investigational medication.
The study focuses on evaluating the safety and effectiveness of the personalized tumor vaccine in generating specific immune responses. It also looks at how the vaccine might affect tumor response and survival outcomes.
- Who can participate: Adults aged 18 and older with advanced solid tumors who have not responded to standard treatments may participate. Participants must have a life expectancy of at least 4 months and meet specific health criteria.
- Study details: Participants will receive a personalized tumor vaccine, possibly with an investigational medication. Some may receive a placebo.